Company news
Ovid Therapeutics Inc. news in 2023
Ovid Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
November 30, 2023
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 2, 2023
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 17, 2023
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 9, 2023
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 25, 2023
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 29, 2023
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 3, 2023
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
July 31, 2023
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 27, 2023
Ovid Therapeutics Added to Russell 3000® Index
June 25, 2023
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 4, 2023
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
April 30, 2023
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 9, 2023
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
March 12, 2023
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
March 8, 2023
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
March 7, 2023
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
February 27, 2023
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
February 7, 2023
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
January 4, 2023
Decks in 2023
- Investor Day (October 2023)
Investor day · 106 slides · Oct 2, 2023